These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25293620)

  • 1. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
    Weiss MJ; Wolfgang CL
    Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
    Kawaida H; Fujii H
    Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
    [No Abstract]   [Full Text] [Related]  

  • 3. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
    Alemi F; Alseidi A; Scott Helton W; Rocha FG
    Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pancreatic cancer- a curable disease].
    Limani P; Samaras P; Lesurtel M; Graf R; DeOliveira ML; Petrowsky H; Clavien PA
    Praxis (Bern 1994); 2015 Apr; 104(9):453-60. PubMed ID: 25900693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma.
    Perrotta G; Mohamed G; Larson BK; Osipov A; Ferrone CR; Lo SK; Gaddam S
    JAMA; 2024 Oct; 332(13):1108-1110. PubMed ID: 39235802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
    Santi I; Brandt A; Hemminki K
    Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
    [No Abstract]   [Full Text] [Related]  

  • 7. Metastatic Pancreatic Cancer.
    Hogendorf P; Durczyński A; Strzelczyk J
    J Invest Surg; 2018 Apr; 31(2):151-152. PubMed ID: 28267398
    [No Abstract]   [Full Text] [Related]  

  • 8. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage III pancreatic cancer and the role of irreversible electroporation.
    Al Efishat M; Wolfgang CL; Weiss MJ
    BMJ; 2015 Mar; 350():h521. PubMed ID: 25787829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
    Hong Y; Rice J; Sharma D; Martin RCG
    Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy in pancreatic cancer.
    Jones OP; Melling JD; Ghaneh P
    World J Gastroenterol; 2014 Oct; 20(40):14733-46. PubMed ID: 25356036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible electroporation for Stage III locally advanced pancreatic cancer: Single-center experience.
    Spiliotis J; Kopanakis N; Terras A; Efstathiou E
    J BUON; 2018; 23(4):1203-1204. PubMed ID: 30358236
    [No Abstract]   [Full Text] [Related]  

  • 13. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Shukla PJ
    Ann Surg; 2011 Aug; 254(2):385-6; author reply 386. PubMed ID: 21677560
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
    Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
    JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
    J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
    Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
    Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
    Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
    Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic ductal carcinoma: from the bench to the bedside.
    Pezzilli R
    JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?
    Bassi C; Crippa S; Salvia R
    Gut; 2008 Mar; 57(3):287-9. PubMed ID: 18268051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.